Between February and March 2026, OpenEvidence made three announcements that individually look like feature updates but collectively represent a strategic transformation.
February 11: Sutter Health collaboration to embed OpenEvidence directly within Epic EHR workflows — giving physicians natural-language search for clinical evidence without leaving the patient's chart.
February 26: Wide release of the AI-Integrated Doctor Dialer — a HIPAA-secure communications suite for telemedicine calls, messaging, faxing, and voicemail, with clinical decision AI embedded directly into the patient communications workflow. The limited-release version had already powered approximately 37 million minutes of doctor-patient communications.
March 26: Launch of Coding Intelligence — automatic ICD-10 diagnoses, E/M recommendations with MDM rationale, and CPT code suggestions with RVU-optimised sequencing.
Each announcement is individually notable. Together, they describe something more ambitious: OpenEvidence is no longer trying to be the best evidence search engine. It is trying to own more of the physician's day.
The Platform Thesis
OpenEvidence's original product was a single tool: ask a clinical question, get a literature-grounded answer with citations. That is Stack 1 — evidence retrieval.
The 2026 expansion adds three new layers. EHR embedding (Sutter/Epic) puts evidence retrieval inside the workflow rather than beside it. Doctor Dialer adds patient communication — calls, messages, faxes — with AI documentation built in. Coding Intelligence adds the revenue layer — billing codes, MDM rationale, reimbursement optimisation.
The resulting platform spans evidence retrieval, clinical documentation, patient communication, and revenue capture. That is not a search engine. That is a clinical operating layer.
What This Means for the Market
OpenEvidence's transformation matters because it validates the convergence thesis: every major clinical AI tool is expanding from its original category into adjacent workflow layers. Scribes are adding pre-charting and coding. Evidence tools are adding documentation and billing. Communication tools are adding clinical intelligence.
The category boundaries that made sense in 2024 — "scribe", "evidence search", "communication tool" — are dissolving. What is emerging is a set of platforms that each want to be the single layer through which clinicians interact with AI across their entire working day.
For clinicians, this means evaluating tools by workflow coverage, not just feature quality. The tool that handles more of your day more seamlessly will displace the tool that handles one task brilliantly but requires you to switch contexts for everything else.
What OpenEvidence Does Not Yet Cover
Despite the expansion, OpenEvidence does not offer adaptive learning, Q-banks, or exam preparation. It does not provide UK-specific guideline grounding (its evidence base is peer-reviewed literature, not NICE/CKS/BNF). It does not offer structured clinical reasoning tools or CPD integration.
For UK clinicians, iatroX covers exactly these gaps: UK guideline-grounded reference via Ask iatroX, structured reasoning via Brainstorm, adaptive learning via the Q-Bank, and professional development via the CPD module. OpenEvidence is becoming a US workflow platform. iatroX remains the UK knowledge and learning platform. The two are complementary rather than competitive.
Conclusion
OpenEvidence is no longer an evidence search engine. It is a workflow platform that spans search, documentation, communication, and billing — with a $12 billion valuation and the largest verified US physician user base of any clinical AI company.
The speed of this transformation — from pure search to full workflow in six weeks of announcements — signals how fast the clinical AI market is consolidating around platforms rather than point solutions. Clinicians who want to understand where the market is heading should watch OpenEvidence carefully. Clinicians who want UK-specific guideline grounding and learning should use iatroX.